These press releases are intended for business journalists and analysts/investors
GSK is honoured to be ranked as #1 on FORTUNE's Change the World list.
Access to human papillomavirus (HPV) vaccination could help to protect the health of millions of women in China at risk from exposure to Human Papillomavirus, the major cause of cervical cancer
GSK Institute for Infectious Diseases and Public Health to partner with Tsinghua University to tackle global public health challenges
GSK today announced a Memorandum of Understanding Agreement between the GSK Institute for Infectious Diseases and Public Health and Tsinghua University School of Medicine (Tsinghua). This 5 year public-private partnership will take on public health challenges in China and globally through scientific and talent exchange as well as joint research programs.
GSK China committed to making newly launched treatment Tivicay® accessible to Chinese people living with HIV
GSK China recently marked the official launch of Tivicay® (dolutegravir), an innovative HIV drug from ViiV Healthcare1, and will continue to work with relevant Chinese government agencies to make it more accessible to people living with HIV in China by its inclusion in China’s free antiretroviral (ARV) programme. On 30 December 2015, Tivicay received approval from the China Food and Drug Administration (CFDA) for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age.
GSK China today committed to reduce the price of its first-line chronic hepatitis B (CHB) treatment, patent-protected Viread® (tenofovir disoproxil fumarate)1, in China by up to 67%. This follows an announcement on the outcomes of a national price negotiation pilot by the National Health and Family Planning Commission (NHFPC) and other relevant government agencies.
GSK delivers strong Q1 performance with sales of £6.2 billion (+8% CER), core EPS 19.8p (+8% CER); dividend of 19p.
2016 core EPS percentage growth now expected to be 10-12% CER.